2023 Invention Litigation Patent Prosecution 
Patently-O
FEBRUARY 10, 2023
2023) This case is still pending before the Federal Circuit, but I found it interesting enough for a preview. United Cannabis holds a broad marijuana patent – US9730911 – with claims directed to a liquid cannabinoid having 95% of either THC or CBD. United Cannabis Corporation v. Pure Hemp Collective Inc. 22-01363 (Fed.
SpicyIP
APRIL 3, 2024
Where the impugned order from the patent office (dated March 18, 2021) ran for 12 pages, the grant order (dated March 05. 2023) resolves the controversy merely in 5 lines. The impugned order also failed to consider the patent granted to the subject invention in different jurisdiction.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SpicyIP
APRIL 10, 2024
DHC Rejects Natco’s Request to Vacate Ceritinib Interim Injunction In a detailed order passed on January 9, 2023, the Delhi High Court had granted an interim injunction to Novartis against Natco, restricting the latter from manufacturing and selling its generic version of Ceritinib, a drug used in treating lung cancer.
Patently-O
JANUARY 23, 2024
Vanda Pharmaceuticals recently filed a petition for writ of certiorari , asking the Supreme Court to review a May 2023 decision by the Federal Circuit that invalidated claims from four Vanda patents covering methods of treating Non-24-Hour Sleep-Wake Disorder (“Non-24”) using the drug tasimelteon (Hetlioz).
SpicyIP
DECEMBER 27, 2021
The debate at the crux of the dispute is, or rather was, the dichotomy between deference to the validity of a granted patent vis-a-vis the challenge to its validity and consequently disregarding the exclusivity granted to it, in litigation. The Drug and the patent. The Litigation. Background . See here and here ).
SpicyIP
DECEMBER 17, 2023
He is interested in IP law, and commercial and criminal litigation. From conflicting positions on AI as a co-author of a work to the contours of information required u/s 39 about the patent applications filed abroad, we had some engaging posts on this blog this week. Sidhi is a final year B.A.
Patently-O
MAY 15, 2024
In my view, the proposed fee increases for continuation applications, RCEs, and excess claims suggest the USPTO is using financial incentives to shape applicant behavior and encourage more compact and focused patent prosecution. This aims to deter competition barriers from multiple patents on obvious variants of an invention.
Expert insights. Personalized for you.
92 
Let's personalize your content